AU2021399925A1 - Masitinib for the treatment of alzheimer's disease - Google Patents

Masitinib for the treatment of alzheimer's disease Download PDF

Info

Publication number
AU2021399925A1
AU2021399925A1 AU2021399925A AU2021399925A AU2021399925A1 AU 2021399925 A1 AU2021399925 A1 AU 2021399925A1 AU 2021399925 A AU2021399925 A AU 2021399925A AU 2021399925 A AU2021399925 A AU 2021399925A AU 2021399925 A1 AU2021399925 A1 AU 2021399925A1
Authority
AU
Australia
Prior art keywords
masitinib
pharmaceutically acceptable
solvate
acceptable salt
baseline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021399925A
Other languages
English (en)
Other versions
AU2021399925A9 (en
Inventor
Colin Mansfield
Alain Moussy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AB Science SA
Original Assignee
AB Science SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AB Science SA filed Critical AB Science SA
Publication of AU2021399925A1 publication Critical patent/AU2021399925A1/en
Publication of AU2021399925A9 publication Critical patent/AU2021399925A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2021399925A 2020-12-16 2021-12-16 Masitinib for the treatment of alzheimer's disease Pending AU2021399925A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20306589 2020-12-16
EP20306589.1 2020-12-16
PCT/EP2021/086308 WO2022129410A1 (en) 2020-12-16 2021-12-16 Masitinib for the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
AU2021399925A1 true AU2021399925A1 (en) 2023-06-29
AU2021399925A9 AU2021399925A9 (en) 2024-10-10

Family

ID=74141317

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021399925A Pending AU2021399925A1 (en) 2020-12-16 2021-12-16 Masitinib for the treatment of alzheimer's disease

Country Status (10)

Country Link
US (1) US20240058328A1 (https=)
EP (1) EP4262801A1 (https=)
JP (1) JP2023554354A (https=)
KR (1) KR20230125804A (https=)
CN (1) CN116963736A (https=)
AU (1) AU2021399925A1 (https=)
CA (1) CA3201259A1 (https=)
IL (1) IL303521A (https=)
MX (1) MX2023007029A (https=)
WO (1) WO2022129410A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025113494A1 (zh) * 2023-11-27 2025-06-05 浙江径科医药有限公司 多环类化合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05001277A (es) 2002-08-02 2005-10-06 Ab Science 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit.
US8153792B2 (en) 2007-02-13 2012-04-10 Ab Science Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors
AR080380A1 (es) * 2010-03-09 2012-04-04 Ab Science Tratamiento de la demencia tipo alzheimer con masitinib

Also Published As

Publication number Publication date
EP4262801A1 (en) 2023-10-25
KR20230125804A (ko) 2023-08-29
IL303521A (en) 2023-08-01
WO2022129410A1 (en) 2022-06-23
CN116963736A (zh) 2023-10-27
CA3201259A1 (en) 2022-06-23
MX2023007029A (es) 2023-07-18
JP2023554354A (ja) 2023-12-27
US20240058328A1 (en) 2024-02-22
AU2021399925A9 (en) 2024-10-10

Similar Documents

Publication Publication Date Title
JP7080944B2 (ja) 細胞生存率を向上させるための組成物およびその使用方法
CA3018635C (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
US20180311236A1 (en) Use of masitinib and other mast cell inhibitors for treatment of parkinson's disease
EA020987B1 (ru) Ассоциация между 4-{3-[цис-гексагидроциклопента[c]пиррол-2(1h)-ил]пропокси}бензамидом и ингибитором ацетилхолинэстеразы и фармацевтические композиции, которые ее содержат
JP7788154B2 (ja) 多発性硬化症患者の亜集団の処置のためのマシチニブ
US20170119760A1 (en) Use of masitinib for the treatment of progressive supranuclear palsy
AU2021399925A1 (en) Masitinib for the treatment of alzheimer's disease
US7816370B2 (en) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
IL293205A (en) Masitinib use for the treatment of eosinophilic asthma
AU2018258970B2 (en) Idalopirdine-based combinatorial therapies of Alzheimer's disease
HK40019381B (zh) 用於提高细胞存活力的组合物和使用该组合物的方法
HK1261581B (zh) 马赛替尼用於治疗肌萎缩侧索硬化症患者亚群的用途
HK1216851B (zh) 用於提高細胞存活力的組合物和使用該組合物的方法

Legal Events

Date Code Title Description
SREP Specification republished